AbbVie’s Rinvoq Delay By US FDA Could Foreshadow More Trouble For JAKs

With JAK inhibitors Under A Cloud Of Scrutiny Over Safety, FDA Seeks More Benefit-Risk Data

The expansion of upadacitinib for a new indication in psoriatic arthritis has been pushed out three months to late in the second quarter.

Paper plane gets stuck in metal fence
High-flying Rinvoq's ascent may be stalled by psoriatic arthritis approval delay • Source: Shutterstock

The US Food and Drug Administration has pushed the decision date on a second indication for AbbVie Inc.'s for Rinvoq out three months to late in the second quarter of 2021 to review additional safety data for the JAK1 inhibitor, the company said on 17 March. The delay and new scrutiny put future revenue potential at risk for a drug AbbVie is relying on to help offset Humira sales declines.

[Sidebar#SC143752]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category